RecruitingPhase 2NCT07024784
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Studying OBSOLETE: Primary peritoneal serous/papillary carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AbbVie
- Principal Investigator
- ABBVIE INC.AbbVie
- Intervention
- IMGN151(drug)
- Enrollment
- 377 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2025 – 2028
Study locations (12)
- Holy Name Medical Center /ID# 279017, Teaneck, New Jersey, United States
- Providence Portland Medical Center /ID# 277727, Portland, Oregon, United States
- Women & Infants Hospital /ID# 277930, Providence, Rhode Island, United States
- SCRI Oncology Partners /ID# 279733, Nashville, Tennessee, United States
- Rabin Medical Center /ID# 279142, Petah Tikva, Central District, Israel
- The Chaim Sheba Medical Center /ID# 275997, Ramat Gan, Tel Aviv, Israel
- Tel Aviv Sourasky Medical Center /ID# 275852, Tel Aviv, Tel Aviv, Israel
- Rambam Health Care Campus- Haifa /ID# 276004, Haifa, Israel
- Shaare Zedek Medical Center /ID# 275854, Jerusalem, Israel
- Hyogo Cancer Center /ID# 276940, Akashi-shi, Hyōgo, Japan
- National Cancer Center Hospital /ID# 276715, Chuo-Ku, Tokyo, Japan
- The Cancer Institute Hospital Of JFCR /ID# 276711, Koto-ku, Tokyo, Japan
Collaborators
GOG Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07024784 on ClinicalTrials.govOther trials for OBSOLETE: Primary peritoneal serous/papillary carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06856499Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian CancerUniversity of Colorado, Denver
- RECRUITINGPHASE3NCT06994195A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian CancerSichuan Baili Pharmaceutical Co., Ltd.
- RECRUITINGNANCT06969833Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube CarcinomaCentre Oscar Lambret
- RECRUITINGPHASE3NCT05659381Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube CancerGOG Foundation
- RECRUITINGNANCT05597683Quadratus Lumborum Block After Cytoreductive Surgery and Hyperthermic Intra-peritoneal ChemotherapyGangnam Severance Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT05456685Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian CancerAbbVie
- RECRUITINGPHASE3NCT05281471Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)Genelux Corporation
- ACTIVE NOT RECRUITINGPHASE2NCT05406674Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian CancerThe Netherlands Cancer Institute
See all trials for OBSOLETE: Primary peritoneal serous/papillary carcinoma →